Similar articles

• A proposal for radical changes in the drug-approval process.

  Wood AJ. Wood AJ. N Engl J Med. 2006 Aug 10;355(6):618-23. doi: 10.1056/NEJMsb055203. N Engl J Med. 2006. PMID: 16899784 No abstract available.
• Mega issues: focusing on the future of dermatology nursing.

  DNA Board of Directors. DNA Board of Directors. Dermatol Nurs. 2004 Apr;16(2):138, 147-8. Dermatol Nurs. 2004. PMID: 15148897
• Dermatology nursing: spreading good practice in primary care.

  Barrett C. Barrett C. J Fam Health Care. 2005;15(2):35. J Fam Health Care. 2005. PMID: 15945491 No abstract available.
• Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials.

  Garmendia CA, Nassar Gorra L, Rodriguez AL, Trepka MJ, Veledar E, Madhivanan P. Garmendia CA, et al. JAMA Intern Med. 2019 Apr 1;179(4):582-584. doi: 10.1001/jamainternmed.2018.7661. JAMA Intern Med. 2019. PMID: 30830216 Free PMC article. Review.
• Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.

  Talley NJ. Talley NJ. Am J Gastroenterol. 2009 Jun;104(6):1339-41. doi: 10.1038/ajg.2009.295. Am J Gastroenterol. 2009. PMID: 19491845 Review. No abstract available.